BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 20
• 22
• 23
• 24
• 25
• 26
• 27
• 30
• 31

• Press Releases

  MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism

  March 9, 2026

   · 

  7 min read
• Press Releases

  First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment

  March 9, 2026

   · 

  7 min read
• Press Releases

  Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026

  March 9, 2026

   · 

  7 min read
• Press Releases

  Koselugo approved in Canada for plexiform neurofibromas in adults with neurofibromatosis type 1

  March 9, 2026

   · 

  8 min read
• Press Releases

  Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS

  March 9, 2026

   · 

  6 min read
• Press Releases

  Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026

  March 9, 2026

   · 

  2 min read
• Press Releases

  Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026

  March 9, 2026

   · 

  1 min read
• Press Releases

  Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection

  March 9, 2026

   · 

  16 min read
• Press Releases

  ITF Therapeutics LLC Presents New Data and Analyses on Givinostat for Treatment of Duchenne Muscular Dystrophy at 2026 MDA Clinical and Scientific Conference

  March 9, 2026

   · 

  9 min read
• Press Releases

  AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

  March 9, 2026

   · 

  6 min read